Press

2025-06-16

Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145

Kancera AB (publ) (Kancera) announces that the World Health Organization has granted rugocrixan and fosrugocrixan as the International Non-proprietary Names for the company’s candidate drugs KAND567 and KAND145.

Read More
2025-06-13

Kancera reports positive top-line results from the KANDOVA study

Kancera AB (publ) (Kancera) today reports the top-line results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian cancer. The primary objective was met – to determine the...

Read More
2025-06-05

Kancera reports positive outcome of pre-IND meeting with FDA

Kancera AB (publ) (Kancera) today reports that it has completed a successful pre-IND meeting with the FDA and received positive feedback on the planned clinical development program for KAND567 in ST-elevation myocardial infarction. The FDA states that it agrees...

Read More
2025-05-23

Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the first quarter 2025 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 11,1 million (SEK 11,4 million). Operating loss for the quarter amounted to...

Read More
2025-05-20

Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program

In connection with the upcoming financial interim report for the first quarter 2025, Kancera AB (publ) (Kancera) provides an update on the ongoing collaboration with Recardio Inc. and the company’s clinical development program and reports that Kancera: conducts joint...

Read More
2025-04-08

Kancera reports Last Patient Last Visit in the KANDOVA study

Kancera AB (publ) reports that the last patient has completed the last visit in the ongoing phase Ib/IIa study KANDOVA evaluating the candidate drug KAND567 in ovarian cancer.

Read More
2025-03-14

Kancera changes Certified Adviser to Redeye AB

Kancera AB (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will take over as Certified Adviser on April 1, 2025.

Read More
2025-03-07

Kancera signs letter of intent agreement with Recardio for licensing of KAND567 and KAND145

Kancera signs letter of intent agreement with US biotech company, Recardio Inc., with the intention to out-license its fractalkine program, including drug candidates KAND567 and KAND145 Recardio’s phase III ready dutogliptin program and Kancera’s fractalkine program in phase II...

Read More
2025-03-07

Kancera announces intention to change company name to Novakand Pharma

Kancera AB (publ) (Kancera) today announces its intention to change the company name to Novakand Pharma, in line with the company’s strategic decision to focus on cardiovascular diseases.

Read More
2025-02-21

Interim Report Fourth Quarter 2024, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the fourth quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 8,5 million (SEK 17,1 million). Operating loss for the quarter amounted to...

Read More